Protocol and apparatus for determining heparin-induced thrombocytopenia
AssigneeHaemoscope Corporation
InventorsEli Cohen, Roslyn Cohen, Roger Carroll
Life of this patent
Estimating the term…
Abstract
A hemostasis analyzer, such as the Thrombelastograph® (TEG®) hemostasis analyzer is utilized to measure continuously in real time, the hemostasis process from the initial fibrin formation, through platelet-fibrin interaction and lysis to generate blood hemostasis parameters. The measured blood hemostasis parameters permit determination of heparin-induced thrombocytopenia II complex (HiT II).
Claims27
A method of determining heparin-induced thrombocytopenia II complex (HiT II) comprising:
- testing a first blood sample to determine a first blood sample characteristic in the presence of heparin;
- testing a second blood sample to determine a second blood sample characteristic in the absence of substantial platelet activation;
- and
- comparing the first blood sample characteristic to the second blood sample characteristic to determine the presence of HiT II.
An apparatus for determining heparin-induced thrombocytopenia II complex (HiT II) comprising:
- means for testing a first blood sample to determine a first blood sample characteristic in the presence of heparin;
- means for testing a second blood sample to determine a second blood sample characteristic in the absence of substantial platelet activation;
- and
- means for comparing the first blood sample characteristic to the second blood sample characteristic to determine the presence of HiT II.
19 The apparatus of claim 12, wherein the first blood sample comprises a first heparinized blood sample prepared with a first quantity of heparin and a second heparinized blood sample prepared with a second quantity of heparin, different than the first quantity of heparin.
A kit for use with a blood hemostasis analyzer for determining heparin-induced thrombocytopenia II complex (HiT II), the kit comprising:
- a plurality of testing vessels, each testing vessel configured to hold a blood sample for testing in the blood hemostasis analyzer;
- a quantity of heparin sufficient to prepare at least one heparinized blood sample for testing;
- and
- a quantity of activator sufficient to activate at least the heparinized blood sample and a non-heparinized blood sample.
Dependencies are inferred from the claim text.